Literature DB >> 25455349

Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline.

Sarah Gourmaud1, Claire Paquet2, Julien Dumurgier2, Clarisse Pace3, Constantin Bouras4, Françoise Gray5, Jean-Louis Laplanche6, Eliane F Meurs7, François Mouton-Liger8, Jacques Hugon9.   

Abstract

BACKGROUND: Alzheimer disease is characterized by cognitive decline, senile plaques of β-amyloid (Aβ) peptides, neurofibrillary tangles composed of hyperphosphorylated τ proteins and neuronal loss. Aβ and τ are useful markers in the cerebrospinal fluid (CSF). C-Jun N-terminal kinases (JNKs) are serine-threonine protein kinases activated by phosphorylation and involved in neuronal death.
METHODS: In this study, Western blots, enzyme-linked immunosorbent assay and histological approaches were used to assess the concentrations of Aβ, τ and JNK isoforms in postmortem brain tissue samples (10 Alzheimer disease and 10 control) and in CSF samples from 30 living patients with Alzheimer disease and 27 controls with neurologic disease excluding Alzheimer disease. Patients with Alzheimer disease were followed for 1-3 years and assessed using Mini-Mental State Examination scores.
RESULTS: The biochemical and morphological results showed a significant increase of JNK3 and phosphorylated JNK levels in patients with Alzheimer disease, and JNK3 levels correlated with Aβ42 levels. Confocal microscopy revealed that JNK3 was associated with Aβ in senile plaques. The JNK3 levels in the CSF were significantly elevated in patients with Alzheimer disease and correlated statistically with the rate of cognitive decline in a mixed linear model. LIMITATIONS: The study involved different samples grouped into 3 small cohorts. Evaluation of JNK3 in CSF was possible only with immunoblot analysis.
CONCLUSION: We found that JNK3 levels are increased in brain tissue and CSF from patients with Alzheimer disease. The finding that increased JNK3 levels in CSF could reflect the rate of cognitive decline is new and merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25455349      PMCID: PMC4409432          DOI: 10.1503/jpn.140062

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  47 in total

Review 1.  Gene-specific regulation by general translation factors.

Authors:  Thomas E Dever
Journal:  Cell       Date:  2002-02-22       Impact factor: 41.582

Review 2.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

3.  Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting.

Authors:  Julien Dumurgier; Olivier Vercruysse; Claire Paquet; Stéphanie Bombois; Chloé Chaulet; Jean-Louis Laplanche; Katell Peoc'h; Susanna Schraen; Florence Pasquier; Jacques Touchon; Jacques Hugon; Sylvain Lehmann; Audrey Gabelle
Journal:  Alzheimers Dement       Date:  2012-11-08       Impact factor: 21.566

Review 4.  Targeting JNK3 for the treatment of neurodegenerative disorders.

Authors:  Lynn Resnick; Myles Fennell
Journal:  Drug Discov Today       Date:  2004-11-01       Impact factor: 7.851

5.  Relation of hippocampal phospho-SAPK/JNK granules in Alzheimer's disease and tauopathies to granulovacuolar degeneration bodies.

Authors:  Sarita Lagalwar; Robert W Berry; Lester I Binder
Journal:  Acta Neuropathol       Date:  2006-11-07       Impact factor: 17.088

6.  A critical role of neural-specific JNK3 for ischemic apoptosis.

Authors:  Chia-Yi Kuan; Alan J Whitmarsh; Derek D Yang; Guanghong Liao; Aryn J Schloemer; Chen Dong; Jue Bao; Kenneth J Banasiak; Gabriel G Haddad; Richard A Flavell; Roger J Davis; Pasko Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

7.  Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein.

Authors:  Elena Tamagno; Michela Guglielmotto; Manuela Aragno; Roberta Borghi; Riccardo Autelli; Luca Giliberto; Giuseppe Muraca; Oliviero Danni; Xiongwei Zhu; Mark A Smith; George Perry; Dong-Gyu Jo; Mark P Mattson; Massimo Tabaton
Journal:  J Neurochem       Date:  2007-11-14       Impact factor: 5.372

8.  MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging.

Authors:  F Fazekas; J B Chawluk; A Alavi; H I Hurtig; R A Zimmerman
Journal:  AJR Am J Roentgenol       Date:  1987-08       Impact factor: 3.959

9.  JNK3 perpetuates metabolic stress induced by Aβ peptides.

Authors:  Sung Ok Yoon; Dong Ju Park; Jae Cheon Ryu; Hatice Gulcin Ozer; Chhavy Tep; Yong Jae Shin; Tae Hee Lim; Lucia Pastorino; Ajaya J Kunwar; James C Walton; Alan H Nagahara; Kun Ping Lu; Randy J Nelson; Mark H Tuszynski; Kun Huang
Journal:  Neuron       Date:  2012-09-06       Impact factor: 17.173

10.  Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease.

Authors:  Julien Dumurgier; Francois Mouton-Liger; Pauline Lapalus; Magali Prevot; Jean-Louis Laplanche; Jacques Hugon; Claire Paquet
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

View more
  39 in total

Review 1.  The Molecular Effects of Environmental Enrichment on Alzheimer's Disease.

Authors:  Anthony Kin Yip Liew; Chuin Hau Teo; Tomoko Soga
Journal:  Mol Neurobiol       Date:  2022-09-09       Impact factor: 5.682

Review 2.  Therapeutic Potential of Allicin and Aged Garlic Extract in Alzheimer's Disease.

Authors:  Paola Tedeschi; Manuela Nigro; Alessia Travagli; Martina Catani; Alberto Cavazzini; Stefania Merighi; Stefania Gessi
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

3.  Radiolabeled Aminopyrazoles as Novel Isoform Selective Probes for pJNK3 Quantification.

Authors:  Brian C Bales; Victoria Cotero; Dan E Meyer; Jeannette C Roberts; Monica Rodriguez-Silva; Tiberiu M Siclovan; Jeremy W Chambers; Michael J Rishel
Journal:  ACS Med Chem Lett       Date:  2022-09-28       Impact factor: 4.632

4.  Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease.

Authors:  Jeffrey Cummings; Andrew Ortiz; Janelle Castellino; Jefferson Kinney
Journal:  Eur J Neurosci       Date:  2022-02-06       Impact factor: 3.698

5.  N-Aromatic-Substituted Indazole Derivatives as Brain-Penetrant and Orally Bioavailable JNK3 Inhibitors.

Authors:  Yangbo Feng; HaJeung Park; Jae Cheon Ryu; Sung Ok Yoon
Journal:  ACS Med Chem Lett       Date:  2021-09-21       Impact factor: 4.632

6.  Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy.

Authors:  Sarah Gourmaud; Haochang Shou; David J Irwin; Kimberly Sansalone; Leah M Jacobs; Timothy H Lucas; Eric D Marsh; Kathryn A Davis; Frances E Jensen; Delia M Talos
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

7.  Olfactory loss in chronic rhinosinusitis is associated with neuronal activation of c-Jun N-terminal kinase.

Authors:  Andrew J Victores; Mengfei Chen; Amy Smith; Andrew P Lane
Journal:  Int Forum Allergy Rhinol       Date:  2017-11-28       Impact factor: 3.858

8.  Evaluation of the Role of JNK1 in the Hippocampus in an Experimental Model of Familial Alzheimer's Disease.

Authors:  Dmitry Petrov; Melani Luque; Ignacio Pedrós; Miren Ettcheto; Sonia Abad; Mercè Pallàs; Ester Verdaguer; Carme Auladell; Jaume Folch; Antoni Camins
Journal:  Mol Neurobiol       Date:  2015-11-12       Impact factor: 5.590

Review 9.  Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer's disease.

Authors:  Mingcui Zheng; Pengwen Wang
Journal:  3 Biotech       Date:  2021-03-20       Impact factor: 2.406

10.  Gene Expression Profile in Different Age Groups and Its Association with Cognitive Function in Healthy Malay Adults in Malaysia.

Authors:  Nur Fathiah Abdul Sani; Ahmad Imran Zaydi Amir Hamzah; Zulzikry Hafiz Abu Bakar; Yasmin Anum Mohd Yusof; Suzana Makpol; Wan Zurinah Wan Ngah; Hanafi Ahmad Damanhuri
Journal:  Cells       Date:  2021-06-27       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.